Formulating for the Future of Transplant Patient Therapy

Transplant Support

Veloxis is a specialty pharmaceutical company committed to improving the lives of transplant patients. Our unique, patented delivery technology, MeltDose®, is designed to enhance the absorption and bioavailability of select orally administered drugs.

Veloxis Pharmaceuticals A/S is headquartered Copenhagen, DK and operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA.

Veloxis is committed to patient access and financial support for kidney transplant patients. Learn more about our prescription cost savings programs, click here Go to


May 17, 2017
Q1 Report 2017 Investor Call

Webcast Webcast

Conference call at 4:00 pm CEST  
Please dial in 5-10 minutes prior to the start time using the number / Conference ID below. 
DK: +4532 71 16 59
US: +1212 444 0412
UK: +44(0)20 3427 1910
NZ: +64(0)9 308 4002
Confirmation Code:  5325377

Stock Information